Toussi · The Journal of urology 2021 · single-center randomized controlled trial · n=82

Efficacy of a Novel Penile Traction Device in Improving Penile Length and Erectile Function Post Prostatectomy: Results from a Single-Center Randomized, Controlled Trial.

Cited 22 times in the scientific literature.

Level 2 - randomized trial

Individual randomized controlled trial

PubMed 34060339 · doi:10.1097/JU.0000000000001792 · record verified 2026-08-27

What was done

Men after prostatectomy were randomized to either a control group or one of two penile traction therapy protocols (RestoreX device) for 6 months, followed by a 3-month open-label phase. The study reported findings from the 6-month randomized phase. The primary outcome was change in stretched penile length. Secondary outcomes included International Index of Erectile Function (IIEF) domain scores, erectogenic medication use, adverse events, and subjective satisfaction.

What was found

A total of 82 men (mean age 58.6 years) were randomized, with 6-month data completed for 55 men (25 controls and 30 traction therapy). At 6 months, penile traction achieved significantly better outcomes compared to control: greater preservation/gain of stretched penile length (+1.6 cm vs +0.3 cm, p <0.01), higher IIEF-Erectile Function scores (+0 vs -6.5, p=0.03), higher IIEF-Intercourse Satisfaction (+1 vs -3.5, p <0.01), and higher IIEF-Overall Sexual Satisfaction (0 vs -3, p <0.01). Use of intracavernosal injections was lower in the traction group (19% vs 50%, p <0.05), while phosphodiesterase-5 inhibitor use was similar (86% vs 94%, p=0.44). Adverse events were mild and transient, with 87% reporting willingness to repeat therapy.

Why it matters

Penile traction therapy provides a non-pharmacological, device-based approach to mitigate penile shortening and sexual dysfunction commonly experienced following radical prostatectomy.

Limits

The trial was conducted at a single center with a modest sample size and substantial attrition (33% lost to follow-up by 6 months). Blinding was not feasible given the physical device intervention, and multicenter external validation is required.

Cited by